Andrew Schorr: Dr. Stadtmauer, related to multiple myeloma what is the role of transplant today?
|
|
- Anastasia Holt
- 5 years ago
- Views:
Transcription
1 The Ongoing Role of Transplant for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Edward Stadtmauer, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. Please have this discussion you re your own doctor, that s how you ll get care that s most appropriate for you. Dr. Stadtmauer, related to multiple myeloma what is the role of transplant today? Well, I really don't try to isolate transplant in the continuum of care for multiple myeloma. My feeling is our goal is to come up with the best combination of treatments in the year 2010, and soon to be 2011, that will lead to the longest productive lives of patients with myeloma. As you know, this last decade has just been a thrilling time for us who care for and for patients who have multiple myeloma in that we have had new agents, the proteasome inhibitors and the immunomodulatory agents, along with high doses of chemotherapy, particularly Melphalan, and autologous stem cell transplant. And these approaches have really led to a tremendously improved outcome. Our enthusiasm for doing high doses of Melphalan and stem cell transplant remains high mainly because there are number studies a couple of studies that are going to be presented at this ASH meeting that suggest that even with the new novel agents, Revlimid and Decadron, as demonstrated by the Eastern Cooperative Oncology Group, and Bortezomib and Thalidomide and Decadron, as demonstrated by the Italian group, that even with those initial therapies and the wonderful responses we're getting, if you add to that a course of high dose Melphalan and autologous stem cell transplant you can even further improve outcome. So how do you know who needs a transplant and who doesn't? Well, again, I don't think of it as who needs one and who doesn't, I think more in terms of who would most benefit by it? And, obviously, patients who have multiple other medical illnesses may have more difficulty with high dose chemotherapy. And we're learning that a aspect of a person called performance status, the ability to walk and move and not have infections and have kidney function that's working very well and have heart function, those things are very important. We would not be giving high doses of chemotherapy to patients who are very debilitated and have other medical illnesses. But in a patient who is well and who is up to the rigors of a course of high dose chemotherapy and stem cell transplant, at least up until a person in their 70s, it looks like there's the potential for improved outcome. 1
2 Doctor, so year after year I ask the same question and that is, is transplant dead, if you will, for multiple myeloma you are a transplanter but I know you want what's best for patients. What's your view at this point? Oh, definitely. Well, once again let me first say that, of course, we have to differentiate the donor bone marrow transplant, the allogeneic bone marrow transplant from the autologous stem cell transplant. And remember, in the autologous stem cell transplant the philosophy is simply to give a dose-intensive chemotherapy. To give more chemotherapy than you could otherwise give to see if you can try to overcome the resistance of a more aggressive myeloma with high doses of chemotherapy and the transplant is simply rescued from the high dose Melphalan. But it's really Melphalan a chemotherapy that is the treatment. And it seems like, at least as far as we know so far, that the best way of giving Melphalan is in that one hour high dose rather than low doses over a long period of time, though there are studies that are looking at that. In an allogeneic transplant, a donor bone marrow transplant, that's where you take you're primarily replacing the organ that is sick, the bone marrow, with someone else's bone marrow. And you replace it by infusing the hematopoietic stem cells from the donor. And, of course, that makes much more logical sense in a disease of the bone marrow, let's replace the sick disease. The problem is every time you infuse someone else's cells into a patient with that, those cells can also cause an immunologic reaction, graph versus host disease, which can lead to other organ dysfunction and is age limiting. So older patients, particularly patients over the age of 60 or so, have a substantially increased risk of an allogeneic transplant. So a lot of people can get confused or much more obviously we have much more concerns with the allogeneic transplant in terms of side effects versus benefit. One of the major reports that is going to be coming out at this meeting is actually a report that I'm involved in, where it's the largest report looking at patients who had newly diagnosed multiple myeloma and then patients who had a perfectly matched brother or sister went on to an autologous stem cell transplant, followed by a mini, or non-myeloablative or reduced-intensity allogeneic, or donor transplant. And the other proportion of patients who did not have a donor, a perfectly matched donor, had an autologous followed by a second autologous. And then we looked three years later and so far what that study is demonstrating is the toxicity of the allogeneic transplant, at least in this group of patients who are under the age of 70, the toxicity of graph versus host disease may not be worth the benefit relative to an autologous stem cell transplant. In other words, at three years both of those groups of patients were doing about the same, and so with allogeneic transplant, at least in that form, it may not be the optimal way of treating the patients. 2
3 Okay, so with medical therapies getting better and more coming and combinations, is it possible, though, that they could manage most myelomas as a chronic condition that you could live well with and not even approach the prospect of a cure through transplant? Well, I am the eternal optimist, and I definitely believe that with we're now third generation, fourth generation, proteasome inhibitors, third generation, and fourth generation immunomodulatory agents. The new chemotherapies, the new ways of targeting therapy, I'm confident that we will continue to improve therapy, the nontransplant therapies in this disease. And I'm confident that there will come a time when we will never use bone marrow transplant in any disease. But, again, the current with the current information we have, until we have data that with the newer agents the results, the ultimate outcomes, the long-term outcomes are the same or superior, which of course is what I hope, to incorporating a cycle or two of high dose Melphalan and stem cell transplant. I think we have to consider that the standard of care in the younger patient with this disease, and I think of it as under age 70, is to think of at least, assess a patient, for incorporation high dose Melphalan and stem cell transplant into that therapy. Doctor, questions that come up from the community, first is a consolidation transplant, what would that be and what would its use be? Well, so I think of the a cycle of high dose of Melphalan and an autologous transplant as consolidation of the remission that's induced by that initial therapy. There remains a question as to doing a second transplant, a second autologous transplant is superior to just doing one, and, in fact, there is a large multi-institution clinical trial sponsored by the National Institutes of Health in the United States that is looking at this question. Currently, they're accruing they're going to approve over 750 patients to a trial that will compare a single transplant to double transplant and hopefully answer that question. In fact, the most interesting arm of that trial, a third arm, is to say, "Well, why don't we do one transplant and then use go back to the Bortezomib and Lenalidomide and Decadron after the transplant and see if we can wipe up the last three cells of myeloma?" So using the newer agents after transplant as a consolidation. So I think that's a really interesting area and there's a lot of work looking at that. Doctor, anybody who's diagnosed with myeloma today wonders since transplant remains one of the options, how do we know whether in their journey it should be earlier or later? 3
4 There are a number of studies that have looked at one versus two auto-transplants in the past. About a decade ago, there were a number of studies that looked at this. And what the studies suggested overall for the entire group of patients, it did look like that two transplants to a superior outcome then a single transplant, of course, this was in the era before the new agents. However, if you did a subset analysis, what it suggested was the patients who after the first transplant still had measurable disease; those were the ones who benefitted the most from the second transplant rather than the ones who were in complete remission after the first transplant. So we're waiting for the new studies to come out to more completely guide us, but as of this moment off of a clinical trial I would say most of us who are considering two transplants would think twice about doing a second transplant in someone who is in a wonderful remission after the first transplant. Okay, and as far as, though, having a transplant to jump ahead of a long course of medical therapy? Oh, that's a really interesting question, the question of whether a transplant can be used instead of continuing chemotherapy. Up until recently that was one of the major blessings of doing a stem cell transplant that you would do it, a patient would be induced into a complete remission or the best remission they can get, and then you would have years of no therapy or perhaps a bisphosphonate for the bone lesions and it was a blessing to not have to be to not take those treatments. Over this last year there have been a number of studies now that do suggest that continued therapy may be better than not taking anything after a stem cell transplant, and the most compelling data comes from two studies; one in a cancer and leukemia comes from two studies; one of them is the CALGB-ECOG trial, which compared patients who had a stem cell transplant to Lenalidomide or placebo and suggested that the patients who took Lenalidomide maintenance therapy had over two years longer duration of remission then patients who didn't take that. There's a similar study from France that showed a very similar outcome, that the patients who took Lenalidomide after a transplant have longer duration of remissions than patients who don't. There will be a study that's presented here at this meeting that looks at a Bortezomib Velcade containing regimen that takes Velcade throughout the initial therapy, and then as a maintenance therapy, versus a non-velcade containing regimen showing significantly improved outcome for the arm that has the continued Velcade versus the one that doesn't. So there's more and more data to suggest that doing something after a stem cell transplant might be better than doing nothing. And so I think the argument that a stem cell transplant will mitigate and ameliorate the need for further therapy afterwards is probably becoming less of an issue. 4
5 For people diagnosed with myeloma today, are you hopeful? I am so hopeful. There is so much interest in this disease. There are so many new developments in multiple myeloma, we have the entire medical community geared up for the next generation of therapies from the physicians, the scientists, the pharmaceutical industry, the nurses, the supportive care, and most importantly, the patients themselves. There are tremendous support groups and resources for patients with multiple myeloma, so no one should go without the information they need and the hope that they need to get through. We've had data on the effectiveness of transplant for myeloma for many years and if you think about it, the novel therapies have been around just for four or five years and they're making a big difference. And there are others coming. So hopefully before long we'll be able to compare those therapies head-to-head with transplant and see if those therapies alone can do the job. Stay tuned. In Orlando, I'm Andrew Schorr. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. Please have this discussion you re your own doctor, that s how you ll get care that s most appropriate for you. 5
More Effective Treatments for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Dan Vogl, M.D.
More Effective Treatments for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Dan Vogl, M.D. Please remember the opinions expressed on Patient Power are not
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationHello and welcome to Patient Power. I'm Andrew Schorr. This program is supported through a grant from Onyx Pharmaceuticals.
The Latest Myeloma News From ASH Breaking News December 21, 2010 Sagar Lonial, M.D. Robert Orlowski, M.D. Jack Aiello Please remember the opinions expressed on Patient Power are not necessarily the views
More informationThis talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse
This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is
More informationDr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust. Natural course of myeloma. Some definitions. First relapse.
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationFour Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014
Patient Power Knowledge. Confidence. Hope. Toward a Cure for Multiple Myeloma: Four Experts Debate Aggressive Treatment Approaches and the Goal of Complete Response Recorded on April 19, 2014 Gareth Morgan,
More informationASH 2014 Coverage: Myeloma Roundtable Discussion Recorded on December 7, 2014
ASH 2014 Coverage: Myeloma Roundtable Discussion Recorded on December 7, 2014 Robert Orlowski, MD, PhD Director of Myeloma and Professor in the Departments of Lymphoma/Myeloma and Experimental Therapeutics,
More informationDo you think you'd be here today if you had not gone to M. D. Anderson?
Advances in Treatment of Multiple Myeloma Webcast November 13, 2007 Michael Wang, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson Cancer Center,
More informationRestrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials
Restrooms Cell phones on silent/vibrate Refreshments Patient resource materials This presentation should not replace discussions with your healthcare provider, but seeks to provide information and resources
More informationAndrew Schorr: Is there anything you ve been discussing that you d like to update people about now?
News from ASH: Advances in Bleeding Disorders ASH Conference Coverage December 8, 2008 Craig Kessler, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors,
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Prof Gordon Cook Professor of Haematology and Myeloma Studies University of Leeds & Leeds Cancer Centre #MyelomaInfodays This talk will cover The
More informationNorthside Multiple Myeloma Support Group Meeting November 3, 2018
November 2018 Northside Multiple Myeloma Support Group Meeting November 3, 2018 Jim M. led the meeting. Jim started the meeting with having everyone introduce himself or herself with a little known fact
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation in the Era of Novel Therapies Larry Anderson, MD, PhD Multiple Myeloma and Stem Cell Transplant
More informationAdvances in Stem Cell Transplant for Multiple Myeloma - The Shift to Outpatient Therapy. Gail Sulski, RN, MS, FNP, AOCNP
Advances in Stem Cell Transplant for Multiple Myeloma - The Shift to Outpatient Therapy Gail Sulski, RN, MS, FNP, AOCNP What s New in Myeloma? Shift to Outpatient Transplant New Drugs with higher remission
More informationInformation and resources for African Americans living with multiple myeloma and their caregivers
For African Americans living with Multiple Myeloma Information and resources for African Americans living with multiple myeloma and their caregivers Standing in the Gaap: An initiative created to help
More informationTreatment options in Myeloma. BritModis myeloma for the elderly care specialist
Treatment options in Myeloma myeloma for the elderly care specialist Dr Richard Soutar, Consultant in Haematology and Transfusion Medicine, Beatson Oncology Centre, Glasgow and The Scottish National Blood
More informationMyeloma XII (ACCoRd) Myeloma Infosheet Series. Clinical trials and novel drugs Infoline:
Myeloma XII (ACCoRd) This Infosheet provides information about what the Myeloma XII clinical trial is, why it is taking place and what is involved if patients decide to take part in the trial. This Infosheet
More informationNew Treatments Bring Hope to Myeloma Patients
THE LATEST NEWS ON TREATING AND LIVING WITH MYELOMA OUR FOCUS ABOUT treatment options New Treatments Bring Hope to Myeloma Patients DR. SEEMA SINGHAL: MYELOMA EXPERT A dose of optimism is standard treatment
More informationOperator Greetings, and welcome to the Living With Myeloma: Managing Side Effects and Quality of Life telephone and Web education program.
WELCOME AND INTRODUCTION Operator Greetings, and welcome to the Living With Myeloma: telephone and Web education program. It is now my pleasure to introduce your moderator,. Thank you, Ms. Figueroa-Rivera.
More informationHematopoietic Stem Cell Transplant in Myeloma. Gary Simmons, DO
Hematopoietic Stem Cell Transplant in Myeloma Gary Simmons, DO Objectives What is the benefit of ASCT What is Upfront therapy and with novel agent era- does it include ASCT Is response before and after
More informationTRANSCRIPT Understanding Next in Class Novel Therapies in Multiple Myeloma: New Classes and Targets
Welcome and Introductions [Slide 1] Thank you so much. Hello everyone and thank you so much for joining us. [Slide 2] This is Joan Levy, and I am the Vice President of Research for the Multiple Myeloma
More informationPatient Case and Question
Management of Multiple Myeloma: The Changing Paradigm Relapsed/Refractory Disease Kenneth H. Shain, MD, PhD Assistant Member H. Lee Moffitt Cancer Center Assistant Professor University of South Florida
More informationMultiple. Powerful thinking advances the cure.
Multiple Myeloma Treatment OVERVIEW Powerful thinking advances the cure www.arztol.com Powerful thinking advances the cure About the Multiple Myeloma Research Foundation The Multiple Myeloma Research Foundation
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Pomalidomide (Pomalyst) for Multiple Myeloma July 31, 2014
pan-canadian Oncology Drug Review Final Economic Guidance Report Pomalidomide (Pomalyst) for Multiple Myeloma July 31, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationTRANSCRIPT Multiple Myeloma Updates From the 2015 ASCO Annual Meeting and 20 th Congress of EHA
Welcome and Introduction Joan Levy, PhD [Slide 1] Hello everyone! [Slide 2] My name is Joan Levy, and I am Vice President of Research at the Multiple Myeloma Research Foundation (MMRF). I d like to welcome
More informationKyprolis. Kyprolis (carfilzomib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.24 Subsection: Antineoplastic Agents Original Policy Date: October 24, 2012 Subject: Kyprolis Page:
More informationBronx, New York Patient-Caregiver Forum November 1, 2017 Page 1 of 9
Bronx, New York Patient-Caregiver Forum November 1, 2017 Page 1 of 9 Speakers: Amit Verma, MD Aditi Shastri, MD Ira Braunschweig, MD Arun Sunny, PA Aditi Shastri, MD: So, I m just going to talk about how
More informationA Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre
A Report on the Molly and David Bloom Chair in Multiple Myeloma Research at the Princess Margaret Cancer Centre April 2013 Table of Contents 1 Introduction 2 Your Support 3 Thank you 10 The Princess Margaret
More informationClinical Policy: Lenalidomide (Revlimid) Reference Number: CP.CPA.275 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationMeet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer
Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer Written by Clara Rodríguez Fernández Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Revlimid) Reference Number: CP.CPA.275 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationTreatment of Multiple Myeloma with Stem Cell Transplantation (SCT)
Treatment of Multiple Myeloma with Stem Cell Transplantation (SCT) Görgün Akpek, MD, MHS Director, SCT and Cellular Therapy Program Banner MD Anderson Cancer Center GAkpek@mdanderson.org MULTIPLE MYELOMA
More informationMyeloma Expert Information About Diagnosis and Treatment
Slide 1: Myeloma Expert Information About Diagnosis and Treatment OPERATOR: Hello, everyone, and welcome to Myeloma Expert Information About Diagnosis and Treatment. It is my pleasure to introduce your
More informationmultiple myeloma cancer coaching introduction
multiple myeloma cancer coaching introduction Hi, my name is David Emerson. I want to welcome you to PeopleBeatingCancer.org s Webinar about the Multiple Myeloma Cancer Coaching Program. I am going to
More informationMultiple Myeloma Update PMMNG 13 Feb Outline. Alfred Garfall MD Edward Stadtmauer MD
Multiple Update PMMNG 13 Feb 2016 Alfred Garfall MD Edward Stadtmauer MD Outline w Updates on existing/approved drugs for multiple myeloma w Updates on new/upcoming drugs and strategies for multiple myeloma
More informationThank you, Lizette. I d like to add my welcome to the patients, caregivers and healthcare professionals attending the program today.
WELCOME AND INTRODUCTION Hello everyone. On behalf of The Leukemia & Lymphoma Society (LLS), a warm welcome to all of you. Special thanks to Dr. Larry Anderson for sharing his time and expertise with us
More informationCAREGIVER GUIDE themmrf.org
MULTIPLE MYELOMA CAREGIVER GUIDE themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters Kathy Giusti
More informationLiving With Myeloma Treatment and Side Effects Management
Slide 1: Welcome & Introductions OPERATOR: Hello, everyone, and welcome to Living With Myeloma Treatment and Side Effects Management, a free telephone/web education program. It is my pleasure to introduce
More informationMultiple Myeloma Research Consortium Clinical Trial Pipeline
Multiple Myeloma Research Consortium Clinical Trial Pipeline Phase 2 Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma NCT02279394 High-Risk
More informationIntegrated Environmental Assessment and Management
Integrated Environmental Assessment and Management IEAM Podcast 8.4 Transcript* Title: California Sediment Quality Objectives, with Steve Bay JENNY SHAW: Hello, and welcome to the podcast for the journal,
More informationMultiple Myeloma, An Issue Of Hematology/Oncology Clinics, 1e (The Clinics: Internal Medicine) By Kenneth C. Anderson MD
Multiple Myeloma, An Issue Of Hematology/Oncology Clinics, 1e (The Clinics: Internal Medicine) By Kenneth C. Anderson MD If you are searching for the ebook Multiple Myeloma, An Issue of Hematology/Oncology
More informationDecember Northside Multiple Myeloma Support Group Meeting December 8, 2018
December 2018 Northside Multiple Myeloma Support Group Meeting December 8, 2018 The Northside group had their Holiday party on the second Saturday of December. It was well attended and lots of homemade
More informationSalvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
Salvage Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Arnon Nagler, M.D., M.Sc Director Hematology Division BMT and Cord Blood Bank Chair Israeli BMT Association Chaim Sheba Medical Center,
More informationFrom Stem Cell to Any Cell
sciencenewsforkids.org http://www.sciencenewsforkids.org/2005/10/from-stem-cell-to-any-cell-2/ From Stem Cell to Any Cell By Emily Sohn / October 11, 2005 For maybe a day, about 9 months before you were
More informationTreatments for newly diagnosed multiple myeloma: analysis of survival data and costeffectiveness
Treatments for newly diagnosed multiple myeloma: analysis of survival data and costeffectiveness evaluation Trippoli S, Messori A, Becagli P, Alterini R, Tendi E Record Status This is a critical abstract
More informationBUILDING AN IDEAL WORLD FOR IMPROVING PATIENT OUTCOMES IN ONCOLOGY. Myeloma Canada s experience
BUILDING AN IDEAL WORLD FOR IMPROVING PATIENT OUTCOMES IN ONCOLOGY Myeloma Canada s experience WHO WE ARE Myeloma Canada is a registered non-profit organization created by, and for people living with multiple
More informationComments on the ACD Received from the Public Through the NICE Website
Comments on the ACD Received from the Public Through the NICE Website xxxxxxxxxxxxxxxxxxxxx Patient MEDICAL PRACTITIONER ( RETIRED) I RETIRED FROM STRONGLY EVIDENCE BASED GENERAL PRACTICE IN 2004 DUE TO
More informationImmunotherapy in myeloma
Immunotherapy in myeloma Horizons Infosheet Clinical trials and novel drugs This Horizons Infosheet provides information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons
More informationStem Cells and Multiple Myeloma
Stem Cells and Multiple Myeloma What is Multiple Myeloma Multiple Myeloma is a cancer of your plasma cells, a type of white blood cell present in your bone marrow Plasma cells normally make proteins called
More informationMultiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA
Multiple Myeloma Highlights From the 2015 ASCO Annual Meeting and the 20 th Congress of EHA July 13, 2015 Welcome and Introductions Anne Quinn Young, MPH Multiple Myeloma Research Foundation Norwalk, CT
More informationInternational Myeloma Foundation Myeloma Action Month Proclamation Kit
International Myeloma Foundation Myeloma Action Month Proclamation Kit A How-To-Guide for Proclamations 2 Finding Your Champion 3 Sample Cover Letter to Legislator 4 Sample Proclamation.. 5-6 Sample Press
More informationEstablishing a National Computer Security Incident Response Team (CSIRT) Transcript
Establishing a National Computer Security Incident Response Team (CSIRT) Transcript Part 1: The Role of a National CSIRT Julia Allen: Welcome to CERT's Podcast Series: Security for Business Leaders. The
More informationDeborah Dunsire, M.D. President and CEO. Annual Meeting of Shareholders Cambridge, MA May 4, 2006
Deborah Dunsire, M.D. President and CEO Annual Meeting of Shareholders Cambridge, MA May 4, 2006 2006 Millennium 2006 Pharmaceuticals Millennium Inc. Pharmaceuticals, Inc. Agenda 2005 Key Accomplishments
More informationInfopack for relapsed and/or refractory myeloma patients. Infoline:
Infopack for relapsed and/or refractory myeloma patients. 1 1 What is relapsed myeloma? 2 How will I know if I am relapsing? 3 Can the timing of relapse be predicted? 4 Treatment at relapse 5 Refractory
More informationMaking the Transition from Advisor to CEO
Making the Transition from Advisor to CEO February 18, 2019 by Robert Huebscher Vanessa Oligino is director of business performance solutions at TD Ameritrade. She leads the content strategy and is responsible
More informationPrincess Margaret Cancer Centre Multiple Myeloma Day Introduction. Anca Prica MD, MSc, FRCPC May 12, 2017
Princess Margaret Cancer Centre Multiple Myeloma Day Introduction Anca Prica MD, MSc, FRCPC May 12, 2017 Who are you? 1) Physician 2) Nurse 3) Pharmacist 4) Trainee 5) Other How many times have you been
More informationTREATMENT OVERVIEW themmrf.org
MULTIPLE MYELOMA TREATMENT OVERVIEW themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters Kathy Giusti
More informationLS Nav 2018 and the road ahead Webinar Q&A
LS Nav 2018 and the road ahead Webinar Q&A 15.02.2018 Presenter Matthias Matthiasson, Product Director, LS Nav Q: Hello. I would like to ask what payment platforms are/will be supported...? A: (I assume
More informationMy PCR Frequently Asked Questions
My PCR Frequently Asked Questions Dear friend, This Frequently Asked Questions (FAQ) booklet has been created for you as part of the My PCR. The booklet contains FAQs prepared by chronic myeloid leukemia
More informationTHE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org
THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters
More informationLiving with Multiple Myeloma. multiple myeloma IRELAND INFORMATION & SUPPORT FOR PATIENTS, FAMILIES AND CARERS. Living with MULTIPLE MYELOMA
multiple myeloma IRELAND INFORMATION & SUPPORT FOR PATIENTS, FAMILIES AND CARERS Living with MULTIPLE MYELOMA 1 Multiple Myeloma Ireland www.multiplemyelomaireland.org Multiple Myeloma Ireland is the only
More informationThe Cost-Benefit Calculus of CT Angiograms
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/heart-matters/the-cost-benefit-calculus-of-ct-angiograms/4047/
More informationHas it ever occurred to you that your coding pattern might cost you money? A lot of money? Up to $45,000 a year, on average, in fact?
Page 1 of 5 Published on pedsource.com (http://www.pedsource.com) E&M Calculator By admin Created 06/04/2008-1:16pm As you are aware, your most common pediatric visits your sick visits are supposed to
More informationThe Myeloma Guide Information for Patients and Caregivers
The Myeloma Guide Information for Patients and Caregivers Manuel, myeloma survivor This publication was supported in part by a grant from Revised 2013 A Message From John Walter President and CEO of The
More informationWell, welcome to this IBM Rational podcast, Why. Agile and DevOps Are Important for Communications Service
IBM Podcast [ MUSIC ] Well, welcome to this IBM Rational podcast, Why Agile and DevOps Are Important for Communications Service Providers. I'm Kimberly Gist with IBM. Communications Service Providers --
More informationMyeloma. Your Essential Guide
Myeloma Your Essential Guide Contents 3 Introduction 4 What is myeloma 7 Types of myeloma 9 What causes myeloma? 10 Diagnosis, tests, investigations and staging 14 Treatment of myeloma 19 Initial treatment
More informationHistory of Drug Development in Multiple Myeloma
History of Drug Development in Multiple Myeloma Myeloma Research Roundtable Scottsdale, AZ March 22, 2013 Robert A. Kyle, MD Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida CP1123175-1 Disclosures
More informationManaging Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know
Managing Patients with Multiple Myeloma: What the Specialty Pharmacist Needs to Know Disclaimer: The information within this CME/CE activity is for continuing education purposes only, and is not intended
More informationMyeloma Treatment and Side Effects Management Update
1 Slide 1: Myeloma Treatment and Side Effects Management OPERATOR: Hello, everyone, and welcome to Myeloma Treatment and Side Effects Management Update, a free telephone/web education program. It is my
More informationMMRF and MMRC. Collaborative Research Model for a Rare Disease. Susan L. Kelley, M.D. MMRF and MMRC 11/23/2009. Collaborative Model
Collaborative Research Model for a Rare Disease Susan L. Kelley, M.D. 1 OVERVIEW Multiple myeloma is an orphan blood cancer with a low 5-year survival rate. African American incidence is twice that of
More informationDaratumumab (Darzalex )
Daratumumab (Darzalex ) This Horizons Infosheet contains information on daratumumab (also known as Darzalex), a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides
More informationMultiple Myeloma. themmrf.org
Multiple Myeloma Caregiver Guide themmrf.org Don t miss out on the latest myeloma updates! Sign up today to receive all of our educational programming and myeloma news! Name: About The Multiple Myeloma
More informationWelcome to this IBM podcast. What is product. line engineering? I'm Angelique Matheny with IBM. It's not
IBM Podcast [ MUSIC ] MATHENY: Welcome to this IBM podcast. What is product line engineering? I'm Angelique Matheny with IBM. It's not easy to build a smarter product. Now try to build more than one at
More informationTrends in Employee Mobility: How to ensure a successful mobile implementation
Trends in Employee Mobility: How to ensure a successful mobile implementation Sponsored by HP Speakers: Bryan Glick, Editor-in-Chief, ComputerWeekly Nikhil Kulkarni, Workplace and Mobility Practice Advisor,
More informationChallenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells. Cell Therapy Liaison Meeting January, 2018
Challenges in Capturing Long Term Follow up of Recipients of Genetically Modified Cells Cell Therapy Liaison Meeting January, 2018 Outline Development of the Cellular Therapy Registry Standardized Data
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell
More informationClinical Trials. Understanding. Multiple Myeloma Cancer of the Bone Marrow. A publication of the International Myeloma Foundation
Multiple Myeloma Cancer of the Bone Marrow Understanding Clinical Trials u-clintrials_en_2018_l5 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800.452.CURE (USA & Canada) 818.487.7455
More informationAris Baras JULY 2018 CRI - PRESENTATION - 17 MINS [MALE RESPONDENT] [Other comments:]
Aris Baras JULY 2018 CRI - PRESENTATION - 17 MINS [MALE RESPONDENT] [Other comments:] Thanks to Sekar for taking us through a good example about having this population scale of genome typing data available
More informationEmployment rights 1: Being/becoming employed
Employment rights 1: Being/becoming employed Cancer and work: is it possible? 1 Employment rights 1: Being/ becoming employed Most people will need to take time off after diagnosis to begin treatment unless
More informationInternational Myeloma Foundation Myeloma Action Month Proclamation Kit
International Myeloma Foundation Myeloma Action Month Proclamation Kit A How-To-Guide for Proclamations 2 Finding Your Champion 3 Sample Cover Letter to Legislator 4 Sample Proclamation 5 Sample Press
More informationJefferies 2017 Healthcare Conference
Jefferies 2017 Healthcare Conference June 9, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information. The
More informationA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma Paul G. Richardson, M.D., Bart Barlogie, M.D., Ph.D., James Berenson, M.D., Seema Singhal, M.D., Sundar Jagannath, M.D., David Irwin, M.D.,
More informationName... Class... Date... In this activity you are going to assess the quality of some science articles written for different publications.
Writing scientifically with stem cells Specification reference: B1.2.3 Stem cells Aims In this activity you are going to assess the quality of some science articles written for different publications.
More informationMULTIPLE MYELOMA Disease Overview
Speak to a patient support nurse PH: 1.866.603.6628 Email: patientnavigator@themmrf.org MULTIPLE MYELOMA Disease Overview Place stamp here Multiple Myeloma Research Foundation 383 Main Avenue, 5th Floor
More informationMULTIPLE MYELOMA Disease Overview
MULTIPLE MYELOMA Disease Overview ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney,
More informationMyeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation
Myeloma Bone Disease Current and Future Treatment A Publication of The Bone and Cancer Foundation What Is Multiple Myeloma? Multiple Myeloma is a cancer that results from a malignant change in a particular
More informationThe Complete Step-By-Step Course to Designing Logos From Start to Finish FROM START TO FINISH
The Complete Step-By-Step Course to Designing Logos From Start to Finish buildingalogo FROM START TO FINISH Building A Logo From Start To Finish No part of this publication may be reproduced, distributed,
More informationHi, I'm Derek Baker, the Executive Editor of the ibm.com home. page, and I'm here today to talk with Dan Pelino, who Is IBM's General Manager for
Hi, I'm Derek Baker, the Executive Editor of the ibm.com home page, and I'm here today to talk with Dan Pelino, who Is IBM's General Manager for the Healthcare and Life Sciences Industries; and also, with
More informationDARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512
DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA Data from the dose-escalation part of the FIH study Abstract #8512 Henk Lokhorst, Torben Plesner, Peter Gimsing, Hareth Nahi, Monique
More informationYgalo - Targeted Alkylator for the Treatment of Myeloma. Pareto Healthcare Conference: September 7 th, 2017
Ygalo - Targeted Alkylator for the Treatment of Myeloma Pareto Healthcare Conference: September 7 th, 2017 Disclaimer IMPORTANT: You must read the following before continuing. The following applies to
More informationRelapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents
Welcome to Managing Myeloma. My name is Adam Cohen, and I am the Director of Myeloma Immunotherapy and an Assistant Professor in the Hematology/Oncology Division at Abramson Cancer Center of the University
More informationManagement of Multiple Myeloma: The Changing Paradigm. Clinical Trials
Management of Multiple Myeloma: The Changing Paradigm Clinical Trials Goal of Clinical Trials: Making Progress Against Myeloma Increase understanding of the disease Improve the way we use currently available
More informationClinical Policy: Thalidomide (Thalomid) Reference Number: ERX.SPMN.95
Clinical Policy: (Thalomid) Reference Number: ERX.SPMN.95 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationInstagram Traffic for E-Commerce
Instagram Traffic for E-Commerce Instagram Basics Instagram is a mobile social network created that is geared strictly to images and videos. Think of it like Twitter but for images and videos. The social
More informationIf you are searching for a book by Mitchel L. Zoler Stem cell transplantation may improve refractory SLE.(News)(systemic lupus erythematosus): An
Stem Cell Transplantation May Improve Refractory SLE.(News)(systemic Lupus Erythematosus): An Article From: Internal Medicine News [HTML] [Digital] By Mitchel L. Zoler READ ONLINE If you are searching
More informationSharing Data: Recovering Registry Addict
Sharing Data: Observations From a Recovering Registry Addict Christopher Bredeson, MD, MSc., FRCPC Director, Hematologic Malignancies Professor of Medicine Medical College of Wisconsin DBV06_1.ppt TODAY
More informationIs Lenalidomide, in Combination with Dexamethasone, a Safe and Effective Treatment for Relapsed Multiple Myeloma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Lenalidomide, in Combination with
More informationBayesian Designs for Early Phase Clinical Trials
Bayesian Designs for Early Phase Clinical Trials Peter F. Thall, PhD Department of Biostatistics M.D. Anderson Cancer Center Fourteenth International Kidney Cancer Symposium Miami, Florida, November 6-7,
More informationEpoetin alfa. Epogen, Procrit (epoetin alfa), Retacrit (epoetin alfa epbx) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.06 Subject: Epoetin alfa Page: 1 of 8 Last Review Date: September 20, 2018 Epoetin alfa Description
More information